Mylan, the maker of EpiPens, an injection device for severe allergy attacks, is trying to persuade the United States Preventive Services Task Force to add the product to the group's list of preventive medical services. That could make EpiPens available to patients with no insurance co-pay. It could also benefit the company by allowing it to raise prices on the product while limiting complaints from the public. The higher prices would be pushed to the government, insurers or employers.
Read Full Article »
